INmune Bio IncNASDAQ:INMB
- LAST PRICE11.2900
- TODAY'S CHANGE (%)0.4500 (4.1513%)
- Bid / Lots11.0300/ 2
- Ask / Lots12.2200/ 10
- Open / Previous Close10.8300 / 10.8400
- Day Range
- 52 Week Range
- Volume77,738
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INMB |
|---|---|---|
| 09:32 ET | 2194 | 11.2 |
| 09:34 ET | 350 | 11.14 |
| 09:38 ET | 452 | 11.18 |
| 09:39 ET | 685 | 11.12 |
| 09:45 ET | 100 | 11.02 |
| 09:50 ET | 200 | 11.17 |
| 09:57 ET | 150 | 11.15 |
| 09:59 ET | 100 | 11 |
| 10:03 ET | 859 | 11.11 |
| 10:06 ET | 1741 | 11.305 |
| 10:12 ET | 2958 | 11.37 |
| 10:19 ET | 230 | 11.36 |
| 10:21 ET | 330 | 11.2156 |
| 10:24 ET | 1999 | 11.3081 |
| 10:26 ET | 1000 | 11.195 |
| 10:28 ET | 300 | 11.1 |
| 10:30 ET | 700 | 11.2 |
| 10:35 ET | 450 | 11.1316 |
| 10:37 ET | 700 | 11.105 |
| 10:46 ET | 200 | 11.14 |
| 10:57 ET | 749 | 11.14 |
| 11:18 ET | 100 | 11.115 |
| 11:36 ET | 100 | 11.24 |
| 11:38 ET | 110 | 11.3099 |
| 11:40 ET | 235 | 11.2818 |
| 11:49 ET | 200 | 11.31 |
| 12:00 ET | 477 | 11.48 |
| 12:03 ET | 500 | 11.485 |
| 12:05 ET | 400 | 11.43 |
| 12:07 ET | 298 | 11.485 |
| 12:12 ET | 1185 | 11.49 |
| 12:18 ET | 2216 | 11.51 |
| 12:20 ET | 1261 | 11.58 |
| 12:21 ET | 616 | 11.6204 |
| 12:30 ET | 3000 | 11.623 |
| 12:34 ET | 700 | 11.64 |
| 12:36 ET | 1100 | 11.6528 |
| 12:50 ET | 600 | 11.72 |
| 01:01 ET | 200 | 11.73 |
| 01:14 ET | 500 | 11.63 |
| 01:15 ET | 1200 | 11.645 |
| 01:17 ET | 700 | 11.62 |
| 01:26 ET | 1275 | 11.5543 |
| 01:37 ET | 200 | 11.52 |
| 01:39 ET | 383 | 11.4108 |
| 01:42 ET | 100 | 11.4 |
| 01:46 ET | 100 | 11.4 |
| 01:55 ET | 100 | 11.4 |
| 02:02 ET | 210 | 11.4 |
| 02:04 ET | 1200 | 11.495 |
| 02:06 ET | 100 | 11.49 |
| 02:26 ET | 800 | 11.545 |
| 02:33 ET | 5097 | 11.545 |
| 02:36 ET | 300 | 11.5477 |
| 02:38 ET | 1085 | 11.545 |
| 02:40 ET | 300 | 11.59 |
| 02:45 ET | 100 | 11.63 |
| 02:49 ET | 413 | 11.64 |
| 02:51 ET | 311 | 11.65 |
| 02:54 ET | 200 | 11.72 |
| 02:56 ET | 200 | 11.65 |
| 02:58 ET | 300 | 11.65 |
| 03:00 ET | 300 | 11.64 |
| 03:02 ET | 300 | 11.64 |
| 03:12 ET | 200 | 11.65 |
| 03:14 ET | 100 | 11.65 |
| 03:18 ET | 100 | 11.65 |
| 03:21 ET | 100 | 11.65 |
| 03:23 ET | 100 | 11.65 |
| 03:25 ET | 1000 | 11.65 |
| 03:30 ET | 216 | 11.6 |
| 03:32 ET | 100 | 11.56 |
| 03:34 ET | 200 | 11.52 |
| 03:38 ET | 1600 | 11.41 |
| 03:39 ET | 100 | 11.325 |
| 03:43 ET | 2131 | 11.2301 |
| 03:45 ET | 200 | 11.2 |
| 03:48 ET | 400 | 11.25 |
| 03:50 ET | 100 | 11.29 |
| 03:52 ET | 300 | 11.27 |
| 03:54 ET | 100 | 11.3 |
| 03:56 ET | 1399 | 11.26 |
| 03:57 ET | 2196 | 11.27 |
| 03:59 ET | 3602 | 11.29 |
Yesterday
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules, from 9:00AM ET on Thursday Apr 25, 2024 by Dow Jones
9:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 23, 2024
Apr 22, 2024
Apr 8, 2024
Mar 28, 2024
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update, from 4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
INmune Bio Inc | 203.5M | -6.8x | --- |
Compass Therapeutics Inc. | 203.6M | -4.3x | --- |
Ovid Therapeutics Inc | 211.4M | -4.2x | --- |
Design Therapeutics Inc | 212.4M | -3.2x | --- |
Actinium Pharmaceuticals Inc | 192.8M | -3.7x | --- |
Merrimack Pharmaceuticals Inc | 214.1M | -178.4x | --- |
Company Information
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Contact Information
- Headquarters
- 225 Ne Mizner Blvd, Suite 640BOCA RATON, FL, United States 33432
- Phone
- 858-964-3720
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Raymond Tesi
- Chief Financial Officer
- David Moss
- Chief Scientific Officer
- Mark Lowdell
- Independent Director
- Marcia Allen
- Independent Director
- Edgardo Baracchini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.5M |
|---|---|
Revenue (TTM) | $155.0K |
Shares Outstanding | 18.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.95 |
EPS | $-1.67 |
Book Value | $2.12 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | 1,313.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19,187.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
